Mangalam Drugs & Organics Limited (BOM:532637)
India · Delayed Price · Currency is INR 73.74
-5.46 (-6.89%)
At close: Aug 28, 2025
Mangalam Drugs & Organics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 2,983 | 3,176 | 3,674 | 3,702 | 4,509 | 3,800 | Upgrade |
| 2,983 | 3,176 | 3,674 | 3,702 | 4,509 | 3,800 | Upgrade | |
Revenue Growth (YoY) | -16.41% | -13.55% | -0.77% | -17.89% | 18.66% | 34.58% | Upgrade |
Cost of Revenue | 1,665 | 1,674 | 2,472 | 2,536 | 3,101 | 2,558 | Upgrade |
Gross Profit | 1,318 | 1,502 | 1,201 | 1,166 | 1,408 | 1,242 | Upgrade |
Selling, General & Admin | 404 | 405.87 | 403.56 | 359.68 | 396.96 | 304.93 | Upgrade |
Other Operating Expenses | 682.15 | 737.99 | 623.42 | 550.29 | 520.32 | 400.29 | Upgrade |
Operating Expenses | 1,258 | 1,310 | 1,173 | 1,020 | 1,020 | 796.97 | Upgrade |
Operating Income | 59.34 | 192.16 | 27.98 | 146.34 | 387.99 | 444.8 | Upgrade |
Interest Expense | -152.14 | -149.33 | -104.09 | -89.21 | -72.02 | -63.21 | Upgrade |
Interest & Investment Income | - | - | 0.96 | 2.98 | 0.01 | 6.22 | Upgrade |
Currency Exchange Gain (Loss) | - | - | - | - | - | 37.43 | Upgrade |
Other Non Operating Income (Expenses) | 4.83 | 5.03 | -35.07 | -37.94 | -39.59 | -30.05 | Upgrade |
EBT Excluding Unusual Items | -87.97 | 47.86 | -110.21 | 22.17 | 276.37 | 395.19 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.89 | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -0.52 | -0.03 | - | - | Upgrade |
Pretax Income | -87.97 | 47.86 | -110.73 | 22.14 | 277.33 | 395.19 | Upgrade |
Income Tax Expense | 9.65 | -19.35 | -20.02 | 9.44 | 80.76 | 115.48 | Upgrade |
Net Income | -97.62 | 67.21 | -90.72 | 12.7 | 196.58 | 279.71 | Upgrade |
Net Income to Common | -97.62 | 67.21 | -90.72 | 12.7 | 196.58 | 279.71 | Upgrade |
Net Income Growth | - | - | - | -93.54% | -29.72% | 238.94% | Upgrade |
Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 16 | 16 | Upgrade |
Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 16 | 16 | Upgrade |
Shares Change (YoY) | 0.01% | -0.09% | - | - | - | - | Upgrade |
EPS (Basic) | -6.17 | 4.25 | -5.73 | 0.80 | 12.42 | 17.67 | Upgrade |
EPS (Diluted) | -6.17 | 4.25 | -5.73 | 0.80 | 12.42 | 17.67 | Upgrade |
EPS Growth | - | - | - | -93.56% | -29.72% | 239.16% | Upgrade |
Free Cash Flow | - | 223.93 | -79.2 | 116.09 | -19.6 | -38.86 | Upgrade |
Free Cash Flow Per Share | - | 14.16 | -5.00 | 7.33 | -1.24 | -2.46 | Upgrade |
Gross Margin | 44.17% | 47.30% | 32.71% | 31.50% | 31.22% | 32.68% | Upgrade |
Operating Margin | 1.99% | 6.05% | 0.76% | 3.95% | 8.61% | 11.71% | Upgrade |
Profit Margin | -3.27% | 2.12% | -2.47% | 0.34% | 4.36% | 7.36% | Upgrade |
Free Cash Flow Margin | - | 7.05% | -2.16% | 3.14% | -0.43% | -1.02% | Upgrade |
EBITDA | 254.71 | 358.23 | 76.84 | 241.08 | 473.58 | 521.14 | Upgrade |
EBITDA Margin | 8.54% | 11.28% | 2.09% | 6.51% | 10.50% | 13.71% | Upgrade |
D&A For EBITDA | 195.37 | 166.07 | 48.86 | 94.74 | 85.6 | 76.34 | Upgrade |
EBIT | 59.34 | 192.16 | 27.98 | 146.34 | 387.99 | 444.8 | Upgrade |
EBIT Margin | 1.99% | 6.05% | 0.76% | 3.95% | 8.61% | 11.71% | Upgrade |
Effective Tax Rate | - | - | - | 42.63% | 29.12% | 29.22% | Upgrade |
Revenue as Reported | 2,990 | 3,182 | 3,687 | 3,727 | 4,512 | 3,847 | Upgrade |
Advertising Expenses | - | - | 12.85 | 13.56 | 24.44 | 6.14 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.